Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Opening Session Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Varsha Gandhi, PhD, on Ibrutinib

Feb

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Opening Session Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Varsha Gandhi, PhD, on Ibrutinib

FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma

Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers

CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax

Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy